A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention

Acne vulgaris, caused by pathophysiological processes at the pilosebaceous unit, is among the most common chronic dermatological disorders. Acne sequelae, including scarring and dyspigmentation, are common, and are often more distressing to patients than active acne lesions, reinforcing the importance of prevention and effective treatment. Trifarotene, a novel fourth generation retinoid selective for retinoid acid receptor gamma, is approved for the management of moderate-to-severe facial and truncal acne, with recent data supporting its efficacy in acne-induced hyperpigmentation. The purpose of this paper is to review treatment modalities for post-inflammatory hyperpigmentation and present trifarotene as a novel, evidence-based topical option.